AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
Isomorphic Labs, a DeepMind spinoff, is set to begin human trials of AI-designed drugs, marking a significant milestone in the use of artificial intelligence for drug discovery. The company's technology, built on DeepMind's AlphaFold platform, has already shown promise in predicting protein structures and designing safe and effective drugs. The trials will test the efficacy of these molecules in humans, potentially leading to breakthroughs in the treatment of various diseases.